Idiopathic pulmonary fibrosis trials in Netherlands

In Netherlands 16 Also abroad 111

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Where
Amsterdam, Heerlen, Nieuwegein
Age
18 years and over
People
139 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525016-41-00 · EU 2025-525016-41-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Where
Heerlen, Nieuwegein
Age
40 years and over
People
324 worldwide
Run by
Contineum Therapeutics
See details and how to joinNCT07284459 · EU 2025-521901-42-00
Phase 2Taking people
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Where
Nieuwegein, Rotterdam
Age
18 years and over
People
340 worldwide
Run by
Avalyn Pharma Inc.
See details and how to joinNCT06951217
Phase 2Not yet taking people in Netherlands
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
Where
Heerlen, Nieuwegein
Age
18 years and over
People
112 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-526404-71-00 · EU 2026-526404-71-00
Phase 3Not yet taking people in Netherlands
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Amsterdam, Heerlen, Leiden, Nieuwegein, Rotterdam
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Where
Amsterdam, Heerlen, Nieuwegein
Age
40 years and over
People
359 worldwide
Run by
AstraZeneca
See details and how to joinNCT07652658
Phase 3Taking people
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Where
Heerlen, Nieuwegein, Nijmegen
Age
40 years and over
People
1,100 worldwide
Run by
PureTech
See details and how to joinNCT07284602 · EU 2025-524493-42-00
Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Where
Heerlen, Rotterdam
Age
40 years and over
People
1,850 worldwide
Run by
United Therapeutics
See details and how to joinNCT04905693
Phase 2Taking people
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Where
Heerlen, Rotterdam, Zutphen
Age
40 years and over
People
240 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07516951 · EU 2024-514246-37-00
Phase 2Taking people
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent
Where
Nieuwegein, Rotterdam
Age
18 years and over
People
128 worldwide
Run by
Avalyn Pharma Inc.
See details and how to join2024-518289-28-00 · EU 2024-518289-28-00
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Where
Amsterdam, Heerlen, Nieuwegein, Rotterdam
Age
18 years and over
People
239 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503697-21-01 · EU 2023-503697-21-01
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Where
Heerlen, Leiden, Nieuwegein, Rotterdam
Age
18 years and over
People
249 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503699-25-00 · EU 2023-503699-25-00
Phase 1Not yet taking people in Netherlands
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
Where
Amsterdam
Age
18 years and over
People
57
Run by
Amsterdam UMC Stichting
See details and how to join2025-521143-20-00 · EU 2025-521143-20-00
No phaseTaking people
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Where
Rotterdam
Age
18 years to 80 years
People
500 worldwide
Run by
University of Massachusetts, Worcester
See details and how to joinNCT06855329
Phase 2Taking people
Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
Where
Amsterdam
Age
18 years and over
People
60
Run by
Amsterdam UMC Stichting
See details and how to join2025-522834-30-01 · EU 2025-522834-30-01
No phaseTaking people
P4O2 ILD Extension
Where
Amsterdam
Age
18 years to 80 years
People
450
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT06644144